Imetelstat (7.5 mg/kg) + lenalidomide standard of care + Imetelstat (9.4 mg/kg)

Phase 2Completed
0 watching 0 views this week Active
47
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Multiple Myeloma

Conditions

Multiple Myeloma

Trial Timeline

Nov 1, 2010 → Nov 1, 2014

About Imetelstat (7.5 mg/kg) + lenalidomide standard of care + Imetelstat (9.4 mg/kg)

Imetelstat (7.5 mg/kg) + lenalidomide standard of care + Imetelstat (9.4 mg/kg) is a phase 2 stage product being developed by Geron for Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT01242930. Target conditions include Multiple Myeloma.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01242930Phase 2Completed